{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:34:11Z","timestamp":1787697251201,"version":"build-2784847793"},"reference-count":59,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eo.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,20]]},"abstract":"<jats:p>Carcinoid syndrome is the most frequent hormonal complication associated with neuroendocrine neoplasms. It was first reported in 1954, and the classical symptoms are diarrhoea, flushing and abdominal pain. It is caused by the secretion of several vasoactive substances, the most prominent being serotonin, which play a pathophysiological role in the clinical symptoms which characterise carcinoid syndrome. Therefore, the focus of carcinoid syndrome treatment is to reduce serotonin production and hence improve the patient\u2019s quality of life. There are a variety of management options for carcinoid syndrome including medical, surgical and loco-regional interventional radiological procedures. The most widely used are somatostatin analogues with three clinically approved drugs: lanreotide and octreotide (first-generation) and pasireotide (second-generation). Both everolimus and interferon used in combination with octreotide have shown significant reduction in urinary 5-hydroxyindoleacetic acid compared to octreotide alone. Telotristat ethyl has been increasingly utilised for patients with symptoms despite taking somatostatin analogues. It has also been shown to have a significant improvement in bowel movement frequency which was associated with a significant improvement in quality of life. Peptide receptor radionuclide therapy has proven symptomatic improvement in patients with uncontrolled symptoms. Chemotherapy is primarily reserved for patients with high proliferation tumours, with limited research on the efficacy in reducing symptoms. Surgical resection remains the optimal treatment due to being the only one that can achieve a cure. Liver-directed therapies are considered in patients where curative resection is not possible. There are therefore numerous different therapies. This paper describes the pathophysiology and therapy of carcinoid syndrome.<\/jats:p>","DOI":"10.1530\/eo-22-0077","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T10:05:44Z","timestamp":1681985144000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":11,"title":["The role of serotonin inhibition within the treatment of carcinoid syndrome"],"prefix":"10.1530","volume":"3","author":[{"given":"Joel","family":"George","sequence":"first","affiliation":[{"name":"Hampshire Hospitals NHS Trust, Basingstoke, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4824-6600","authenticated-orcid":true,"given":"John","family":"Ramage","sequence":"additional","affiliation":[{"name":"Hampshire Hospitals NHS Trust, Basingstoke, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"White","sequence":"additional","affiliation":[{"name":"Hampshire Hospitals NHS Trust, Basingstoke, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-8681","authenticated-orcid":true,"given":"Rajaventhan","family":"Srirajaskanthan","sequence":"additional","affiliation":[{"name":"Kings Health Partners NET Centre of Excellence, London, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Seminars in Nuclear Medicine","first-page":"447","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors","volume":"50","author":"Basu","year":"2020","unstructured":"Basu SParghane RVKamaldeep & Chakrabarty S2020 Peptide receptor radionuclide therapy of neuroendocrine tumors. Seminars in Nuclear Medicine50447\u2013464. (https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.05.004)"},{"key":"bib2","series-title":"Life Sciences","first-page":"1271","article-title":"Differences in the degradation of hypothalamic releasing factors by rat and human serum","volume":"19","author":"Benuck","year":"1976","unstructured":"Benuck M & Marks N1976Differences in the degradation of hypothalamic releasing factors by rat and human serum. Life Sciences191271\u20131276. (https:\/\/doi.org\/10.1016\/0024-3205(7690263-0)"},{"key":"bib3","series-title":"Annual Review of Medicine","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","unstructured":"Berger MGray JA & Roth BL2009The expanded biology of serotonin. Annual Review of Medicine60 355\u2013366. (https:\/\/doi.org\/10.1146\/ANNUREV.MED.60.042307.110802)"},{"key":"bib4","series-title":"Endocrine-Related Cancer","first-page":"R115","article-title":"Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum","volume":"25","author":"Bla\u017eevi\u0107","year":"2018","unstructured":"Bla\u017eevi\u0107 AHofland JHofland LJFeelders RA & De Herder WW2018Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. Endocrine-Related Cancer25R115\u2013R130. (https:\/\/doi.org\/10.1530\/ERC-17-0380)"},{"key":"bib5","series-title":"Transplantation Proceedings","first-page":"2195","article-title":"The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation","volume":"30","author":"B\u00f6hler","year":"1998","unstructured":"B\u00f6hler TWaiser JBudde KLichter SJauho AFritsche LKorn A & Neumayer HH1998The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplantation Proceedings302195\u20132197. (https:\/\/doi.org\/10.1016\/S0041-1345(9800588-0)"},{"key":"bib6","series-title":"World Journal of Gastroenterology","first-page":"2118","article-title":"Healthcare and economic impact of diarrhea in patients with carcinoid syndrome","volume":"22","author":"Broder","year":"2016","unstructured":"Broder MSChang ERomanus DCherepanov D & Neary MP2016Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World Journal of Gastroenterology222118\u20132125. (https:\/\/doi.org\/10.3748\/wjg.v22.i6.2118)"},{"key":"bib7","series-title":"Endocrine Connections","first-page":"1082","article-title":"Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection","volume":"8","author":"Calanchini","year":"2019","unstructured":"Calanchini MTadman MKrogh JFabbri AGrossman A & Shine B2019Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection. Endocrine Connections81082\u20131088. (https:\/\/doi.org\/10.1530\/EC-19-0269)"},{"key":"bib8","series-title":"Journal of Clinical Medicine","first-page":"1","article-title":"Indications of peptide receptor radionuclide therapy (Prrt) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review","volume":"10","author":"Camus","year":"2021","unstructured":"Camus BCottereau ASPalmieri LJDermine STenenbaum FBrezault C & Coriat R2021Indications of peptide receptor radionuclide therapy (Prrt) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review. Journal of Clinical Medicine101\u201318. (https:\/\/doi.org\/10.3390\/jcm10061267)"},{"key":"bib9","series-title":"Journal of Clinical Oncology","first-page":"2304","article-title":"Lenvatinib in patients with advanced Grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the Phase II Talent trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","unstructured":"Capdevila JFazio NLopez CTeul\u00e9 AValle JWTafuto SCustodio AReed NRaderer MGrande E, 2021Lenvatinib in patients with advanced Grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the Phase II Talent trial (GETNE1509). Journal of Clinical Oncology392304\u20132312. (https:\/\/doi.org\/10.1200\/JCO.20.03368)"},{"key":"bib10","series-title":"New England Journal of Medicine","first-page":"224","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","unstructured":"Caplin MEPavel M\u0106wik\u0142a JBPhan ATRaderer MSedl\u00e1\u010dkov\u00e1 ECadiot GWolin EMCapdevila JWall L, 2014Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine371224\u2013233. (https:\/\/doi.org\/10.1056\/NEJMoa1316158)"},{"key":"bib11","series-title":"Clinical Therapeutics","first-page":"2006","article-title":"Relationship between symptoms and health-related quality-of-life benefits in patients with carcinoid syndrome: post hoc analyses from TELESTAR","volume":"40","author":"Cella","year":"2018","unstructured":"Cella DBeaumont JLHudgens SMarteau FFeuilly MHouchard ALapuerta PRamage JPavel MH\u00f6rsch D, 2018Relationship between symptoms and health-related quality-of-life benefits in patients with carcinoid syndrome: post hoc analyses from TELESTAR. Clinical Therapeutics402006\u20132020.e2. (https:\/\/doi.org\/10.1016\/j.clinthera.2018.10.008)"},{"key":"bib12","series-title":"Journal of the American College of Surgeons","first-page":"432","article-title":"Hepatic neuroendocrine metastases: does intervention alter outcomes?","volume":"190","author":"Chamberlain","year":"2000","unstructured":"Chamberlain RSCanes DBrown KTSaltz LJarnagin WFong Y & Blumgart LH2000Hepatic neuroendocrine metastases: does intervention alter outcomes?Journal of the American College of Surgeons190432\u2013445. (https:\/\/doi.org\/10.1016\/S1072-7515(0000222-2)"},{"key":"bib13","series-title":"Cancer","first-page":"3212","article-title":"A prospective, phase 1\/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor","volume":"119","author":"Chan","year":"2013","unstructured":"Chan JABlaszkowsky LStuart KZhu AXAllen JWadlow RRyan DPMeyerhardt JGonzalez MRegan E, 2013A prospective, phase 1\/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer1193212\u20133218. (https:\/\/doi.org\/10.1002\/CNCR.28142)"},{"key":"bib14","series-title":"Endocrine-Related Cancer","first-page":"1","article-title":"Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors","volume":"22","author":"Cives","year":"2015","unstructured":"Cives MKunz PLMorse BCoppola DSchell MJCampos TNguyen PTNandoskar PKhandelwal V & Strosberg JR2015Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocrine-Related Cancer221\u20139. (https:\/\/doi.org\/10.1530\/ERC-14-0360)"},{"key":"bib15","series-title":"World Journal of Gastroenterology","first-page":"6857","article-title":"Direct costs of carcinoid syndrome diarrhea among adults in the United States","volume":"25","author":"Dasari","year":"2019","unstructured":"Dasari AJoish VNPerez-Olle RDharba SBalaji K & Halperin DM2019Direct costs of carcinoid syndrome diarrhea among adults in the United States. World Journal of Gastroenterology256857\u20136865. (https:\/\/doi.org\/10.3748\/wjg.v25.i47.6857)"},{"key":"bib16","series-title":"Journal of Endocrinological Investigation","first-page":"563","article-title":"Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid)","volume":"29","author":"Dav\u00ec","year":"2006","unstructured":"Dav\u00ec MVBodei LFrancia GBartolomei MOliani CScilanga LReghellin DFalconi MPaganelli GLo Cascio V, 2006Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). Journal of Endocrinological Investigation29563\u2013567. (https:\/\/doi.org\/10.1007\/BF03344149)"},{"key":"bib17","series-title":"Journal of Gastrointestinal Cancer","first-page":"212","article-title":"Time to sustained improvement in bowel movement frequency with telotristat ethyl: analyses of Phase III studies in carcinoid syndrome","volume":"52","author":"Dillon","year":"2021","unstructured":"Dillon JSKulke MHH\u00f6rsch DAnthony LBWarner RRPBergsland EWelin SO\u2019Dorisio TMKunz PLMcKee C, 2021Time to sustained improvement in bowel movement frequency with telotristat ethyl: analyses of Phase III studies in carcinoid syndrome. Journal of Gastrointestinal Cancer52212\u2013221. (https:\/\/doi.org\/10.1007\/s12029-020-00375-2)"},{"key":"bib18","series-title":"New England Journal of Medicine","first-page":"1103","article-title":"Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome","volume":"277","author":"Engelman","year":"1967","unstructured":"Engelman KLovenberg W & Sjoerdsma A1967Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. New England Journal of Medicine2771103\u20131108. (https:\/\/doi.org\/10.1056\/NEJM196711232772101)"},{"key":"bib19","series-title":"Reviews in Endocrine and Metabolic Disorders","first-page":"599","article-title":"Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications","volume":"21","author":"Fanciulli","year":"2020","unstructured":"Fanciulli GRuggeri RMGrossrubatscher ECalzo Lo FWood TDFaggiano AIsidori A & Colao A2020Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications. Reviews in Endocrine and Metabolic Disorders21599\u2013612. (https:\/\/doi.org\/10.1007\/S11154-020-09547-8\/TABLES\/6)"},{"issue":"Supplement 1","key":"bib20","series-title":"Clinics","first-page":"e490s","article-title":"Carcinoid syndrome: update on the pathophysiology and treatment","volume":"73","author":"Ferrari","year":"2018","unstructured":"Ferrari ACGlasberg JP & Riechelmann RP2018Carcinoid syndrome: update on the pathophysiology and treatment. Clinics73(Supplement 1) e490s. (https:\/\/doi.org\/10.6061\/clinics\/2018\/e490s)"},{"key":"bib21","series-title":"Endokrynologia Polska","first-page":"362","article-title":"The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours","volume":"63","author":"Foltyn","year":"2012","unstructured":"Foltyn WZaje\u00e7ki WMarek BKajdaniuk DSiemin\u015bka LZemczak A & Kos-Kuda\u0142 B2012The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours. Endokrynologia Polska63362\u2013366."},{"key":"bib22","series-title":"Health and Quality of Life Outcomes","first-page":"18","article-title":"Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study","volume":"5","author":"Fr\u00f6jd","year":"2007","unstructured":"Fr\u00f6jd CLarsson GLampic C & Von Essen L2007Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health and Quality of Life Outcomes518. (https:\/\/doi.org\/10.1186\/1477-7525-5-18)"},{"key":"bib23","series-title":"International Journal of Molecular Sciences","article-title":"Somatostatin analogs in clinical practice: a review","volume":"21","author":"Gomes-Porras","year":"2020","unstructured":"Gomes-Porras MC\u00e1rdenas-Salas J & \u00c1lvarez-Escol\u00e1 C2020Somatostatin analogs in clinical practice: a review. International Journal of Molecular Sciences211682. (https:\/\/doi.org\/10.3390\/IJMS21051682)"},{"key":"bib24","series-title":"HPB","first-page":"345","article-title":"Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors","volume":"9","author":"Gomez","year":"2007","unstructured":"Gomez DMalik HZAl-Mukthar AMenon KVToogood GJLodge JPA & Prasad KR2007Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB9345\u2013351. (https:\/\/doi.org\/10.1080\/13651820701504199)"},{"key":"bib25","series-title":"Seminars in Interventional Radiology","first-page":"28","article-title":"Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases","volume":"30","author":"Gupta","year":"2013","unstructured":"Gupta S2013Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Seminars in Interventional Radiology3028\u201338. (https:\/\/doi.org\/10.1055\/s-0033-1333651)"},{"key":"bib26","series-title":"Lancet. Oncology","first-page":"525","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","unstructured":"Halperin DMShen CDasari AXu YChu YZhou SShih YT & Yao JC2017Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet. Oncology18525\u2013534. (https:\/\/doi.org\/10.1016\/S1470-2045(1730110-9)"},{"key":"bib27","series-title":"Pharmaceuticals","article-title":"Lutathera\u00ae: the first FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","unstructured":"Hennrich U & Kopka K2019Lutathera\u00ae: the first FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals12114. (https:\/\/doi.org\/10.3390\/ph12030114)"},{"key":"bib28","series-title":"Endocrine-Related Cancer","first-page":"R145","article-title":"Management of carcinoid syndrome: a systematic review and meta-analysis","volume":"26","author":"Hofland","year":"2019","unstructured":"Hofland JHerrera-Mart\u00ednez ADZandee WT & De Herder WW2019Management of carcinoid syndrome: a systematic review and meta-analysis. Endocrine-Related Cancer26R145\u2013R156. (https:\/\/doi.org\/10.1530\/ERC-18-0495)"},{"key":"bib29","series-title":"Acta Oncologica","first-page":"225","article-title":"Long-term management of the carcinoid syndrome treatment with octreotide alone and in combination with alpha-interferon","volume":"32","author":"Janson","year":"1993","unstructured":"Janson ET & \u00d6berg K1993Long-term management of the carcinoid syndrome treatment with octreotide alone and in combination with alpha-interferon. Acta Oncologica32225\u2013229. (https:\/\/doi.org\/10.3109\/02841869309083916)"},{"key":"bib30","series-title":"Journal of the National Comprehensive Cancer Network","first-page":"765","article-title":"Liver-directed therapies in patients with advanced neuroendocrine tumors","volume":"10","author":"Jones","year":"2012","unstructured":"Jones NBShah MH & Bloomston M2012Liver-directed therapies in patients with advanced neuroendocrine tumors. Journal of the National Comprehensive Cancer Network10765\u2013774. (https:\/\/doi.org\/10.6004\/jnccn.2012.0076)"},{"key":"bib31","series-title":"Archives of Internal Medicine","first-page":"26","article-title":"The carcinoid crisis","volume":"114","author":"Kahil","year":"1964","unstructured":"Kahil MEBrown H & Fred HL1964The carcinoid crisis. Archives of Internal Medicine11426\u201328. (https:\/\/doi.org\/10.1001\/ARCHINTE.1964.03860070072004)"},{"key":"bib32","series-title":"Neuroendocrinology","first-page":"245","article-title":"Enets consensus guidelines for the standards of care in neuroendocrine tumors: pre-and perioperative therapy in patients with neuroendocrine tumors","volume":"105","author":"Kaltsas","year":"2017","unstructured":"Kaltsas GCaplin MDavies PFerone DGarcia-Carbonero RGrozinsky-Glasberg SH\u00f6rsch DJanson ETKianmanesh RKos-Kudla B, 2017Enets consensus guidelines for the standards of care in neuroendocrine tumors: pre-and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology105245\u2013254. (https:\/\/doi.org\/10.1159\/000461583)"},{"key":"bib33","series-title":"Endocrine Reviews","first-page":"458","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","unstructured":"Kaltsas GABesser GM & Grossman AB2004The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews25458\u2013511. (https:\/\/doi.org\/10.1210\/ER.2003-0014)"},{"key":"bib34","series-title":"Neuroendocrinology","first-page":"274","article-title":"Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects","volume":"101","author":"Koumarianou","year":"2015","unstructured":"Koumarianou AKaltsas GKulke MHOberg KStrosberg JRSpada FGaldy SBarberis MFumagalli CBerruti A, 2015Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects. Neuroendocrinology101274\u2013288. (https:\/\/doi.org\/10.1159\/000430816)"},{"key":"bib35","series-title":"New England Journal of Medicine","first-page":"663","article-title":"Treatment of the malignant carcinoid syndrome","volume":"315","author":"Kvols","year":"1986","unstructured":"Kvols LKMoertel CGO\u2019Connell MJSchutt AJRubin J & Hahn RG1986Treatment of the malignant carcinoid syndrome. New England Journal of Medicine315663\u2013666. (https:\/\/doi.org\/10.1056\/NEJM198609113151102)"},{"key":"bib36","series-title":"Annals of Surgical Oncology","first-page":"171","article-title":"Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience","volume":"17","author":"Martin","year":"2010","unstructured":"Martin RCGScoggins CR & McMasters KM2010Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Annals of Surgical Oncology17171\u2013178. (https:\/\/doi.org\/10.1245\/S10434-009-0686-Z)"},{"key":"bib37","series-title":"Yale Journal of Biology and Medicine","first-page":"271","article-title":"The role of interferons in the treatment of malignant neoplasms","volume":"62","author":"Murren","year":"1989","unstructured":"Murren JR & Buzaid AC1989The role of interferons in the treatment of malignant neoplasms. Yale Journal of Biology and Medicine62271\u2013290."},{"key":"bib38","series-title":"Surgery","first-page":"1057","article-title":"Aggressive surgery for metastatic liver neuroendocrine tumors","volume":"134","author":"Norton","year":"2003","unstructured":"Norton JAWarren RSKelly MGZuraek MBJensen RTFahey TJThompson NWSnyder SKPasieka JLMitchell B, 2003Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery1341057\u20131063. (https:\/\/doi.org\/10.1016\/j.surg.2003.07.025)"},{"issue":"Supplement 2","key":"bib39","series-title":"Annals of Oncology","first-page":"S111","article-title":"Chemotherapy and biotherapy in the treatment of neuroendocrine tumours","volume":"12","author":"\u00d6berg","year":"2001","unstructured":"\u00d6berg K2001Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Annals of Oncology12(Supplement 2) S111\u2013S114. (https:\/\/doi.org\/10.1093\/annonc\/12.suppl_2.s111)"},{"key":"bib40","series-title":"Journal of Thoracic Disease","first-page":"4308","article-title":"Morbidity, mortality and long-term outcome of lung cancer resections performed in palliative intent","volume":"11","author":"Palade","year":"2019","unstructured":"Palade EG\u00fcnter JGomez JMMWellner UFSchmid SWiesemann S & Passlick B2019Morbidity, mortality and long-term outcome of lung cancer resections performed in palliative intent. Journal of Thoracic Disease114308\u20134318. (https:\/\/doi.org\/10.21037\/jtd.2019.09.61)"},{"key":"bib41","series-title":"Annals of Oncology","first-page":"1569","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study","volume":"28","author":"Pavel","year":"2017","unstructured":"Pavel MEBaudin E\u00d6berg KEHainsworth JDVoi MRouyrre NPeeters MGross DJ & Yao JC2017Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Annals of Oncology281569\u20131575. (https:\/\/doi.org\/10.1093\/annonc\/mdx193)"},{"key":"bib42","series-title":"Lancet","first-page":"2005","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","unstructured":"Pavel MEHainsworth JDBaudin EPeeters MH\u00f6rsch DWinkler REKlimovsky JLebwohl DJehl VWolin EM, 2011Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet3782005\u20132012. (https:\/\/doi.org\/10.1016\/S0140-6736(1161742-X)"},{"key":"bib43","series-title":"Supportive Care in Cancer","first-page":"3695","article-title":"Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden","volume":"24","author":"Pearman","year":"2016","unstructured":"Pearman TPBeaumont JLCella DNeary MP & Yao J2016Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Supportive Care in Cancer243695\u20133703. (https:\/\/doi.org\/10.1007\/S00520-016-3189-Z)"},{"key":"bib44","series-title":"Science","first-page":"329","article-title":"Crystalline serotonin","volume":"108","author":"Rapport","year":"1948","unstructured":"Rapport MMGreen AA & Page IH1948Crystalline serotonin. Science108329\u2013330. (https:\/\/doi.org\/10.1126\/SCIENCE.108.2804.329)"},{"key":"bib45","series-title":"Journal of Clinical Oncology","first-page":"4656","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","unstructured":"Rinke AM\u00fcller HHSchade-Brittinger CKlose KJBarth PWied MMayer CAminossadati BPape UFBl\u00e4ker M, 2009Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology274656\u20134663. (https:\/\/doi.org\/10.1200\/JCO.2009.22.8510)"},{"key":"bib46","series-title":"Transplantation","first-page":"386","article-title":"Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors","volume":"73","author":"Rosenau","year":"2002","unstructured":"Rosenau JBahr MJVon Wasielewski RMengel MSchmidt HHJNashan BLang HKlempnauer JManns MP & Boeker KHW2002Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation73386\u2013394. (https:\/\/doi.org\/10.1097\/00007890-200202150-00012)"},{"key":"bib47","series-title":"Cancer Management and Research","first-page":"7537","article-title":"Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes","volume":"11","author":"Saavedra","year":"2019","unstructured":"Saavedra CBarriuso JMcnamara MGValle JW & Lamarca A2019Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Management and Research117537\u20137556. (https:\/\/doi.org\/10.2147\/CMAR.S181439)"},{"key":"bib48","series-title":"Cancer Control","first-page":"127","article-title":"A Review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract","volume":"18","author":"Strosberg","year":"2011","unstructured":"Strosberg JRCheema A & Kvols LK2011A Review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control18127\u2013137. (https:\/\/doi.org\/10.1177\/107327481101800207)"},{"key":"bib49","series-title":"Endocrine-Related Cancer","first-page":"469","article-title":"Surgery for midgut carcinoid","volume":"10","author":"Sutton","year":"2003","unstructured":"Sutton RDoran HEWilliams EMIVora JVinjamuri SEvans JCampbell FRaraty MGTGhaneh PHartley M, 2003Surgery for midgut carcinoid. Endocrine-Related Cancer10469\u2013481. (https:\/\/doi.org\/10.1677\/erc.0.0100469)"},{"key":"bib50","series-title":"Cancer","first-page":"2902","article-title":"The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment","volume":"116","author":"Svejda","year":"2010","unstructured":"Svejda BKidd MGiovinazzo FEltawil KGustafsson BIPfragner R & Modlin IM2010The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer1162902\u20132912. (https:\/\/doi.org\/10.1002\/CNCR.25049)"},{"key":"bib51","series-title":"Cancer Treatment Reviews","first-page":"1","article-title":"Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two Australian tertiary medical institutions","volume":"66","author":"Tapia Rico","year":"2018","unstructured":"Tapia Rico GLi MPavlakis NCehic G & Price TJ2018Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two Australian tertiary medical institutions. Cancer Treatment Reviews661\u20136. (https:\/\/doi.org\/10.1016\/j.ctrv.2018.03.002)"},{"key":"bib52","series-title":"Pancreas","first-page":"405","article-title":"A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs)","volume":"42","author":"Tellez","year":"2013","unstructured":"Tellez MRMamikunian GO\u2019Dorisio TMVinik AI & Woltering EA2013A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas42405\u2013410. (https:\/\/doi.org\/10.1097\/MPA.0b013e318271c0d5)"},{"key":"bib53","series-title":"Clinical Medicine Insights. Endocrinology and Diabetes","first-page":"1179551419884058","article-title":"Management of gastrointestinal neuroendocrine tumors","volume":"12","author":"Wang","year":"2019","unstructured":"Wang RZheng-Pywell RChen HABibb JAChen H & Rose JB2019Management of gastrointestinal neuroendocrine tumors. Clinical Medicine Insights. Endocrinology and Diabetes121179551419884058. (https:\/\/doi.org\/10.1177\/1179551419884058)"},{"key":"bib54","series-title":"Clinical Therapeutics","first-page":"952","article-title":"Changes in weight associated with telotristat ethyl in the treatment of carcinoid syndrome","volume":"40","author":"Weickert","year":"2018","unstructured":"Weickert MOKaltsas GH\u00f6rsch DLapuerta PPavel MValle JWCaplin MEBergsland EKunz PLAnthony LB, 2018Changes in weight associated with telotristat ethyl in the treatment of carcinoid syndrome. Clinical Therapeutics40952\u2013962.e2. (https:\/\/doi.org\/10.1016\/j.clinthera.2018.04.006)"},{"key":"bib55","series-title":"Gastrointestinal Cancer Research","first-page":"161","article-title":"The expanding role of somatostatin analogs in the management of neuroendocrine tumors","volume":"5","author":"Wolin","year":"2012","unstructured":"Wolin EM2012The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointestinal Cancer Research5161\u2013168."},{"key":"bib56","series-title":"Drug Design, Development and Therapy","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","unstructured":"Wolin EMJarzab BEriksson BWalter TToumpanakis CMorse MATomassetti PWeber MMFogelman DRRamage J, 2015Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Design, Development and Therapy9 5075\u20135086. (https:\/\/doi.org\/10.2147\/DDDT.S84177)"},{"key":"bib57","series-title":"Journal of Clinical Oncology","first-page":"3063","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","unstructured":"Yao JCHassan MPhan ADagohoy CLeary CMares JEAbdalla EKFleming JBVauthey JNRashid A, 2008One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology263063\u20133072. (https:\/\/doi.org\/10.1200\/JCO.2007.15.4377)"},{"key":"bib58","series-title":"New England Journal of Medicine","first-page":"514","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","unstructured":"Yao JCShah MHIto TBohas CLWolin EMVan Cutsem EHobday TJOkusaka TCapdevila Jde Vries EGE, 2011Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine364514\u2013523. (https:\/\/doi.org\/10.1056\/NEJMoa1009290)"},{"key":"bib59","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"e3665","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome","volume":"106","author":"Zandee","year":"2021","unstructured":"Zandee WTBrabander TBlazevi\u0107 AMinczeles NSFeelders RADe Herder WW & Hofland J2021Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome. Journal of Clinical Endocrinology and Metabolism106e3665\u2013e3672. (https:\/\/doi.org\/10.1210\/clinem\/dgab289)"}],"container-title":["Endocrine Oncology"],"original-title":[],"link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/3\/1\/EO-22-0077.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/3\/1\/EO-22-0077.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/3\/1\/EO-22-0077.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:50:28Z","timestamp":1784555428000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/eo\/article\/1549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":59,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eo-22-0077","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}